mRAGE Sperm Health Screening for DNA Damage Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for evaluating sperm health in the context of male infertility are invasive, time-consuming, and do not adequately report on sperm health, particularly due to the lack of effective extracellular markers for DNA fragmentation and oxidative stress.
Innovation Solution
The use of membrane-bound receptor for advanced glycation end products (mRAGE) as a biomarker to evaluate sperm health through quantitative or qualitative measurement, allowing for the identification and removal of damaged sperm.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional sperm selection methods (morphology, motility, concentration) are used, then the selection process is simple and quick, but the accuracy of identifying healthy sperm is insufficient leading to poor IVF/ICSI outcomes
Solution Approach 1:
The patent segments the sperm selection process into multiple independent assessment dimensions: morphology evaluation, motility analysis, DNA fragmentation assessment, and acrosome status evaluation. Each dimension is evaluated separately using specific staining protocols and imaging parameters, allowing comprehensive health assessment without requiring a single complex device.
Solution Approach 2:
The patent introduces specific staining agents as intermediaries to enhance the detectability of sperm health parameters. Stains such as DAPI for DNA, acrosome stains, and mitochondrial membrane potential indicators serve as mediators that convert biological properties into optically detectable signals, improving measurement precision without directly complicating the core imaging system.
2Measurement precision
If advanced sperm evaluation methods are implemented, then the accuracy of sperm health assessment is improved, but the time required for evaluation increases
Solution Approach 1:
The patent implements preliminary staining and preparation steps that simultaneously prepare multiple evaluation parameters for concurrent assessment. By pre-staining sperm samples with multiple markers before imaging, the system enables parallel evaluation of morphology, DNA integrity, and acrosome status in a single imaging session rather than sequential testing.
Solution Approach 2:
The patent transitions from two-dimensional morphological assessment to three-dimensional evaluation by incorporating depth information and multiple focal planes. Confocal or optical sectioning capabilities allow simultaneous assessment of sperm head, midpiece, and tail structures in three dimensions, providing comprehensive evaluation without requiring multiple separate imaging sessions.
3Adaptability or versatility
If multiple sperm parameters are evaluated simultaneously, then the comprehensiveness of sperm health assessment is improved, but the difficulty of detection and measurement increases
Solution Approach 1:
The patent applies different staining protocols and imaging parameters to specific regions of the sperm cell based on local functional requirements. The head region receives DNA stains for chromatin assessment, the midpiece receives mitochondrial stains for energy assessment, and the acrosome receives specific fluorescent markers. This localized approach enables comprehensive evaluation while simplifying detection by matching measurement techniques to specific cellular compartments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides a reliable, less invasive method to assess sperm health by correlating mRAGE expression with mitochondrial dysfunction, DNA fragmentation, and motility, enabling the purification of healthy sperm.
Implementation Method 1
A method of evaluating sperm health and identifying sperm to be used in assisted reproductive technologies comprises providing a sample of sperm, applying a staining protocol to the sample of sperm, and evaluating the stained sperm cells based on multiple parameters including morphology, motility, concentration, DNA fragmentation, and acrosome status
Data Source
Figure 1a~1c
Figure 2i~2vi
Figure 3a~3f
AI summary
The present invention relates to a method of evaluating sperm health and identifying sperm to be used in Assisted Reproductive Technologies by providing a biological sample from a patient, preferably a semen sample; measuring the quantitative level of a biomarker in the sample; and evaluating sperm health based on the quantitative level of the biomarker, wherein the biomarker is membrane-bound receptor for advanced glycation end products (mRAGE).